Spinout Perspectum secures FDA clearance, closes $5m round

12th November 2015

Perspectum announced today it has been given US FDA clearance to market its test for diagnosing and measuring liver disease.

The company also announced it has closed a $5m financing round. Investors include the University of Oxford and Oxford University Hospitals NHS Trust.

Perspectum has received 510(k) clearance from the US Food and Drug Administration (FDA) for its LiverMultiScan test, which uses magnetic resonance imaging to detect early liver disease.

The device is the only imaging test cleared to detect early-stage liver disease, which affects more than 15 per cent of people in the US and 10 per cent of people in the UK.

LiverMultiScan offers a quantitative liver assessment in a safe, non-invasive 15-minute MRI scan.

The platform is now positioned for marketing in the United States and set for a formal launch at the 2015 American Association for the Study of Liver Disease (AASLD) Liver Meeting November 13-17, 2015 in San Francisco.

Perspectum was spun out by Oxford University Innovation in 2012 founded by a team from Oxford’s Radcliffe Department of Medicine.

For more detail please visit Perspectum’s website or read the full announcement here.

Press release sign up